ALAR PHARMACEUTICALS INC.
Update：2026/03/31
Industries
Main Industry
Biotechnology
Main Product/Service
Different from the current long-acting technologies, drug products developed by our unique long-acting release platform (In-Relar) have distinctive characteristics such as low viscosity solution, small injection volume, and sustained drug release profile,
Founded Year
2016
Unified Business No.
52310651
Status
Active
Number of Employees
0
Total Paid-in
Capital
668,000,000 (NT$)
Location of Company
Taiwan
, Taichung City
Exit Status
OTC listing(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Alar Pharmaceuticals Inc., established in 2016, is a new drug development company focusing on developing long-acting release drug products for CNS disorders and chronic diseases. Aiming to submit the new drug application via the 505(b)(2) regulatory pathway and address the unmet medical needs, long-acting injectables for treating opioid use disorder, chronic pain, treatment-resistant depression, and other diseases are under development. Long-acting release products could not only relieve the burden of daily medication, enhance patient’s compliance, and increase drug adherence, but could also improve medical quality and have greater potential to achieve treatment success.
